Biomarkers in Lung Cancer: Current Applications and Future Prospects for Precision Medicine

Join us for this dynamic, livestream, CME-certified webinar where experts will discuss the latest clinical data, including from ASCO Virtual 2021, on predictive biomarkers and how to apply them to guide optimal use of targeted therapies and immunotherapies in the care of your patients with lung cancer. The program will feature roundtable discussions and you will have the opportunity to submit your questions to the expert panel throughout the program.

Not an official event of the 2021 ASCO Annual Meeting. Not sponsored, endorsed, or accredited by ASCO, CancerLinQ, or Conquer Cancer. 

To Register: On the Event Dates page click a date/time, click blue Register button in upper right-hand corner. Once registered, you will receive a reminder email with a link to join in advance of the Webinar.


  • Welcome and Introduction
  • Current Standard of Care for Molecular Testing in NSCLC
  • New and Emerging Predictive Biomarkers for Targeted Therapies in NSCLC
    • EGFR
    • ALK, RET, KRAS
    • EGFR exon 20 insertions, HER2
    • METex14, ROS1, NTRK
  • Current and Emerging Biomarkers Predicting Response to Immune-Based Therapies in NSCLC
  • Final Panel Discussion and Audience Question and Answer Session


Date / Time
Event Details


Program Director
Suresh Ramalingam, MD, FACP, FASCO

Professor of Hematology and Medical Oncology
Roberto C. Goizueta Chair for Cancer Research
Division of Medical Oncology
Assistant Dean for Cancer Research
Emory University School of Medicine
Deputy Director, Winship Cancer Institute
Atlanta, Georgia

Stephen V. Liu, MD

Associate Professor of Medicine
Department of Medical Oncology
Lombardi Comprehensive Cancer Center
Georgetown University
Washington, DC

Lecia V. Sequist, MD, MPH

The Landry Family Professor of Medicine
Harvard Medical School
Director, Center for Innovation in Early Cancer Detection
Massachusetts General Hospital
Boston, Massachusetts

Goal Statement
The goal of this activity is to educate physicians and other healthcare professionals about the recent improvements in the care of NSCLC and applying those improvements to their patients.

Target Audience
This program is intended for physicians and other healthcare providers who care for patients with non-small-cell lung cancer.

Learning Objectives
Upon completion of this activity, participants should be able to:

  • Assess new and emerging predictive biomarkers to guide precision treatment decisions in patients with NSCLC
  • Discuss the practical aspects of biomarker testing and interpretation, including benefits/limitations of different testing methodologies/platforms/assays and other nuances
  • Summarize the available data and expert recommendations to determine which biomarkers should be tested in your patients with lung cancer
  • Identify patients eligible for ongoing clinical trials of emerging biomarkers for NSCLC


Joint Accreditation Statement

In support of improving patient care, Clinical Care Options, LLC (CCO) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.

Physician Continuing Medical Education

Credit Designation 

CCO designates this live activity for a maximum of 2.0 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Disclosure of Conflicts of Interest
Clinical Care Options, LLC (CCO) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose all financial conflicts of interest (COI) they may have with ineligible companies. All relevant COI are thoroughly vetted and mitigated according to CCO policy. CCO is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.